BZE2204 / Shanghai Cell Therapy Group - LARVOL DELTA

JL-lightning CAR-T, a next generation non-viral CAR-T without in-vitro culturing procedure, shows high clinical efficacy, good safety with low treatment dosage (AACR 2025) - "In vitro experiments showed both versions of BZE2204 exerted strong cytotoxicity on CD19-, CD22- and BCMA-positive tumor cells with high CAR-T cell expansion rates, superior stemness and low exhaustion phenotype compared with conventional CAR-T. V-6h, which has the shortest process, displayed the highest T-stem and proliferation among all groups. In vivo models showed V-30h BZE2204 inhibited tumor growth and significantly prolonged mice lifespan under super low dosage (1E5 CAR-T/mouse)."

Preclinical • Hematological Malignancies • Lymphoma • Oncology • CD22

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL) (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: Shanghai Cell Therapy Group Co.,Ltd

CAR T-Cell Therapy • New P1 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology